Paraneoplastic Cerebellar Degeneration
By Richard
Hopper
Harvard University Graduate School of Education
Email: Richard_Hopper@gse.harvard.edu
(Modified Dec.12/98)
What is Paraneoplastic Cerebellar Degeneration (PCD)?
A paraneoplastic syndrome is an autoimmune disease, similar to diseases such as Lupus,
rheumatoid arthritis or psoraisis. A neoplasm is a cancer, whereas a
paraneoplasm is an antibody produced by a patients own immune system to
keep cancer at bay - sort of like natures chemotherapy. In most cases these
cancer-fighting antibodies focus their attack on the cancer cells. A paraneoplastic
syndrome occurs when a cancer victim produces antibodies that end up attacking not only
the cancer, but also healthy cells. In rare instances the paraneoplastic antibodies attack
the cerebellum, the area of the brain located at the lower back of the head, just above
the brain stem and below the cerebral cortex. The cerebellum is responsible for all the
wonderful things we take for granted: balance, swallowing, voice volume, fine motor
coordination, eye movement, etc.
What happens to a person with PCD is that his/her own immune systems produce hostile
antibodies which are transported through the circulatory system. These antibodies are
found in blood plasma, but somehow make their way past the brain-blood barrier into the
spinal fluid and "bathe" the cerebellum. The problem with PCD suffers is that
the cancer antibodies attack the layer of cells in the cerebellum called the perkinje
cells. Perkinje cells are the communicator cells for the cerebellum - sort of like
transmitters of information to the cerebral cortex, the larger "thinking" part
of the brain. The antibodies kill off perkinje cells, causing atrophy or degeneration of
the cerebellum, thereby disturbing the communication path to the cerebral cortex. This
cerebellar degeneration causes a host of symptoms which can vary from patient to patient,
but which include ataxia (uncontrolled gait and loss of fine
motor coordination), dysarthria (slurred speech), dysphagia (difficulty swallowing),
hypotonia (loss of muscle tone), nystagmus (repeated uncontrollable movement of the eyes),
vomiting and vertigo (the two are not necessarily related, but can be), uncontrollable
voice volume, Parkinsons tremors and a variety of other physical symptoms. In some
cases patients can also experience dementia, blindness, and memory loss. Patients
generally exhibit a unique combination of these and other neurological symptoms.
What can be done to treat PCD?
The most important thing is to get a rapid diagnosis. PCD is most common in patients with
lung, breast, ovarian, or lymphatic cancers. Some patients are diagnosed with PCD before
locating their primary cancer. The syndrome can also appear well after tumor excision,
chemotherapy, and radiation have already taken place. Some patients have great difficulty
identifying the location of their cancer. These patients are said to have
"occult" or hidden cancers that are hard to detect even after many scans, blood
tests, and biopsies. PCD effects almost as many women as men, but is very slightly more
common in males. There have been some reported cases where the symptoms have abated upon
tumor excision, chemotherapy, radiation, etc. It is therefore important to locate the
source of the cancer and work to eradicate it, if at all possible.
There are other diseases such at Kreutzfeld Jacob disease (related to the "mad
cow" disease), Freidricks Ataxia, or cerebellar tumors which can also cause severe
ataxia. It is therefore important to get a proper diagnosis through antibody testing.
Until recently the antibody test was generally done on spinal fluid which is extracted
through a lumbar puncture, and now diagnosis can be done with a simple blood
test--speeding-up diagnosis and treatment.
In addition to treatment of the primary cancer, PCD patients can also undergo
"plasmapheresis" a sort of blood dialysis in which the plasma is replaced with
saline solution or other fluid in an effort to flush out the antibodies that are causing
the harm. This blood cleansing technique can ease the symptoms of PCD, and can sometimes
arrest any progression of neurological dysfunction so it is important that patients avail
themselves of this treatment as soon as possible.
Some patients respond to steroids such as Cortisone, Prednisone, or Prelone. Some doctors
may wish to try using a steroid-stimulating hormone called ACTH as an alternative. There
is also the possibility of treatment with IVIG, or intravenous gamma globulin, as well as
Cytoxin, a chemotherapy drug called cyclophosphamide.
How else might we combat the neurological deficits of PCD?
Physical therapy, speech therapy, and occupational therapy can help patients to recover
some function. Another effective technique is aquatherapy. Aquatherapy is assisted
"walking" in a pool with the help of therapists and flotation devices. The water
helps helps patients with severe ataxia to feel a greater sense of freedom and ease of
motion. Some aquatherapy centers have open hours in which patients can use the specially
equipped pool with friends or family members who have received some basic training in
appropriate techniques.
PCD patients are also hypercoagulopathic, meaning that their blood clots easily,
presenting a risk of pulmonary embolisms and the like. Physical therapy important on this
basis alone: regular exercise will help the patient lessen his/her risk of blood clots by
staying as active as possible; aquatherapy can be one way to do that.
What sort of research is being done on PCD?
Much of the research on PCD is limited, as it is an extremely rare disorder. The primary
concern of physicians is understandably treatment of the underlying cancer. Many
physicians hold the belief that Paraneoplastic Cerebellar Degeneration is an untreatable
sign of imminent death and therefore find it to be an unfruitful area for research.
This is an unfortunate attitude, since understanding the antibodies related to
paraneoplastic syndromes might actually help us to better fight cancer. If paraneoplastic
antibodies are meant to kill cancer cells, then why not learn to harness their power to
produce a controlled assault on cancer cells rather than brain cells, thereby creating a
new therapy to fight cancer? One physician concerned with just this topic is Dr. Jerome
Posner of Memorial Sloan Kettering Cancer Center in New York City (Neuro-Oncology).
Some hospitals doing research on PCD are: